Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for business professionals · Thursday, March 28, 2024 · 699,459,600 Articles · 3+ Million Readers

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, LOGM and HTHT

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE)
Class Period: December 14, 2017 to August 7, 2018
Lead Plaintiff Deadline: October 24, 2018

During the class period, Ampio Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.

Get additional information about the AMPE lawsuit: http://www.kleinstocklaw.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3

Nevro Corp. (NYSE: NVRO)
Class Period: January 8, 2018 to July 12, 2018
Lead Plaintiff Deadline: October 22, 2018

Throughout the class period, Nevro Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza I and Senza II systems; (2) as a result, Nevro's Senza I and Senza II systems were not "novel" or "proprietary;" (3) these practices caused Nevro to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro's U.S. sales growth was not sustainable; and (5) consequently, defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the NVRO lawsuit: http://www.kleinstocklaw.com/pslra-1/nevro-corp-loss-form?wire=3

Lannett Company, Inc. (NYSE: LCI)
Class Period: February 7, 2018 to August 17, 2018
Lead Plaintiff Deadline: October 26, 2018

The complaint alleges that during the class period Lannett Company, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Lannett faced a substantial risk of the loss of its exclusivity agreement with Jerome Stevens Pharmaceuticals; (2) accordingly, Lannett’s reported revenues were unsustainable; and (3) as a result, Lannett’s public statements were materially false and misleading at all relevant times.

Get additional information about the LCI lawsuit: http://www.kleinstocklaw.com/pslra-1/lannett-company-inc-loss-form?wire=3

LogMeIn, Inc. (NASDAQ: LOGM)
Class Period: March 1, 2017 to July 26, 2018
Lead Plaintiff Deadline: October 19, 2018

The complaint alleges that throughout the class period LogMeIn, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) LogMeIn’s business practices had negatively impacted renewal rates for certain of its services; and (2) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Following this news, shares of LogMeIn fell $26.60 to close at $77.85 per share on July 27, 2018.

Get additional information about the LOGM lawsuit: http://www.kleinstocklaw.com/pslra-c/logmein-inc?wire=3

Huazhu Group Limited (NASDAQ: HTHT)
Class Period: May 14, 2018 to August 28, 2018
Lead Plaintiff Deadline: December 7, 2018

The complaint alleges that during the class period Huazhu Group Limited made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate security measures to protect customer information; (2) as a result of the foregoing, the Company would be susceptible to increased litigation risk and higher expenses; (3) as a result of the foregoing, the Company’s goodwill would potentially suffer, leading to lower revenues; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the HTHT lawsuit: http://www.kleinstocklaw.com/pslra-1/huazhu-group-limited-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

Klein NEW logo black transparent.png

Powered by EIN News
Distribution channels: Consumer Goods, Law


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release